Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801707 · ClinicalTrials.gov registry record · Phase 2
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
A Phase 2 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT03801707 is a Phase 2 study that has completed, run by Ohio State University. The registered enrollment target is 54 participants.
The verdict
NCT03801707, a Phase 2 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
Interventions
- DRUG Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
- DRUG Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03801707
The ClinicalTrials.gov registry entry for NCT03801707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] is the first listed.
NCT03801707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03801707 about?
NCT03801707 is a clinical study titled "Utilization of Hepatitis C Positive Kidneys in Negative Recipients". To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
What is the current status of trial NCT03801707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2019-03-22. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT03801707?
The interventions under investigation include: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] (DRUG), Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] (DRUG).
Who is sponsoring clinical trial NCT03801707?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.